Top

Published in:

01-11-2014 | Original Article

Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters

Authors: Pengtao Pan, Xiaoyi Han, Fangqian Li, Qingfeng Fu, Xiang Gao, Hui Sun, Li Wang

Published in: Endocrine | Issue 2/2014

Abstract

The goal of the present study was to investigate whether p53 antibodies (Abs) could be a relevant marker for papillary thyroid carcinoma (PTC). Three types of enzyme-linked immunosorbent assay (ELISA) methods were developed for the detection of p53 Abs, including p53-ELISA, phage-SS-ELISA, and phage-SP-ELISA. A total of 304 patients, including 117 cases with thyroid adenoma and 187 PTC patients, were enrolled in this study. Expression of p53 protein and mutation in BRAF gene were evaluated in paraffin-embedded tissue from 44 patients with PTC, in order to elucidate their correlations with the presence of p53 Abs. Compared with p53-ELISA and phage-SS-ELISA, phage-SP-ELISA presented the highest detection efficiency of p53 Abs in patients with PTC, and a combination of these three ELISA systems could make the detection of p53 Abs more sensitive than using each of the individual ELISA methods. Furthermore, p53 Abs was positively associated with clinical stage (P = 0.044), node metastasis (P = 0.010), and p53 protein accumulation (P = 0.019). These results indicate that serum p53 Abs could be a useful marker for PTC.

L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)PubMedCrossRef

S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638–2648 (1998)PubMedCrossRef

D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, R.M. Tuttle, American Thyroid Association Guidelines Taskforce, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006)PubMedCrossRef

T. Kunavisarut, Diagnostic biomarkers of differentiated thyroid cancer. Endocrine 44, 616–622 (2013)PubMedCrossRef

Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson, D. Sidransky, BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625–627 (2003)PubMedCrossRef

M.N. Nikiforova, Y.E. Nikiforov, Molecular diagnostics and predictors in thyroid cancer. Thyroid 19, 1351–1361 (2009)PubMedCrossRef

M. Xing, D. Clark, H. Guan, M. Ji, A. Dackiw, K.A. Carson, M. Kim, A. Tufaro, P. Ladenson, M. Zeiger, R. Tufano, BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977–2982 (2009)PubMedCrossRefPubMedCentral

L. Crawford, D. Pim, R. Bulbrook, Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30, 403–408 (1982)PubMedCrossRef

T. Soussi, p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60, 1777–1788 (2000)PubMed

10.

V. Goodell, L.G. Salazar, N. Urban, C.W. Drescher, H. Gray, R.E. Swensen, M.W. McIntosh, M.L. Disis, Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24, 762–768 (2006)PubMedCrossRef

11.

C. Chapman, A. Murray, J. Chakrabarti, A. Thorpe, C. Woolston, U. Sahin, A. Barnes, J. Robertson, Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 18, 868–873 (2007)PubMedCrossRef

12.

M. Lechpammer, J. Lukač, S. Lechpammer, D. Kovačević, M. Loda, Z. Kusić, Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 19, 114–120 (2004)PubMedCrossRef

13.

R. Ralhan, S. Arora, T.K. Chattopadhyay, N.K. Shukla, M. Mathur, Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int. J. Cancer 85, 791–795 (2000)PubMedCrossRef

14.

R. Tang, M.C. Ko, J.Y. Wang, C.R. Changchien, H.H. Chen, J.S. Chen, K.C. Hsu, J.M. Chiang, L.L. Hsieh, Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 94, 859–863 (2001)PubMedCrossRef

15.

P. Lenner, F. Wiklund, S. Emdin, C. Arnerlöv, C. Eklund, G. Hallmans, H. Zentgraf, J. Dillner, Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer 79, 927–932 (1999)PubMedCrossRefPubMedCentral

16.

J. Bourhis, R. Lubin, B. Roche, S. Koscielny, J. Bosq, I. Dubois, M. Talbot, P. Marandas, G. Schwaab, P. Wibault, B. Luboinski, F. Eschwege, T. Soussi, Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88, 1228–1233 (1996)PubMedCrossRef

17.

R.J. Gao, H.Z. Bao, Q. Yang, Q. Cong, J.N. Song, L. Wang, The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res. Treat. 93, 111–115 (2005)PubMedCrossRef

18.

N. Gandra, G. Abbineni, X. Qu, Y. Huai, L. Wang, C. Mao, Bacteriophage Bionanowire as a Carrier for Both Cancer-Targeting Peptides and Photosensitizers and its use in Selective Cancer Cell Killing by Photodynamic Therapy. Small 9, 215–221 (2013)PubMedCrossRefPubMedCentral

19.

D.H. Yu, J.H. Li, Y.C. Wang, J.G. Xu, P.T. Pan, L. Wang, Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12–5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin. Chim. Acta 412, 930–935 (2011)PubMedCrossRef

20.

K.S. Anderson, J. Wong, A. Vitonis, C.P. Crum, P.M. Sluss, J. Labaer, D. Cramer, p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 19, 859–868 (2010)PubMedCrossRefPubMedCentral

21.

S.A. McNeil, S.A. Halperin, J.M. Langley, B. Smith, A. Warren, G.P. Sharratt, D.M. Baxendale, M.A. Reddish, M.C. Hu, S.D. Stroop, J. Linden, L.F. Fries, P.E. Vink, J.B. Dale, Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114–1122 (2005)PubMedCrossRef

22.

C.J. Chapman, A. Murray, J.E. McElveen, U. Sahin, U. Luxemburger, Ö. Türeci, Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63, 228–233 (2008)PubMedCrossRef

23.

J.Y. Zhang, C.A. Casiano, X.X. Peng, J.A. Koziol, E.K. Chan, E.M. Tan, Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 12, 136–143 (2003)PubMed

24.

S.J. Chatterjee, R. Datar, D. Youssefzadeh, B. George, P.J. Goebell, J.P. Stei, L. Young, S.R. Shi, C. Gee, S. Groshen, D.G. Skinner, R.J. Cote, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007–1013 (2004)PubMedCrossRef

25.

R. Zigeuner, O. Tsybrovskyy, M. Ratschek, P. Rehak, K. Lipsky, C. Langner, Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63, 1079–1083 (2004)PubMedCrossRef

26.

R. Lubin, B. Schlichtholz, D. Bengoufa, G. Zalcman, J. Tredaniel, A. Hirsch, C. Caron de Fromentel, C. Preudhomme, P. Fenaux, G. Fournier, P. Mangin, P. Laurent-Puig, G. Pelletier, M. Schlumberger, F. Desgrandchamps, A. Le Duc, J.P. Peyrat, N. Janin, B. Bressac, T. Soussi, Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 53, 5872–5876 (1993)PubMed

27.

B. Schlichtholz, J. Tredaniel, R. Lubin, G. Zalcman, A. Hirsch, T. Soussi, Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer 69, 809–816 (1994)PubMedCrossRefPubMedCentral

28.

F. Di Marzo Veronese, A.E. Willis, C. Boyer-Thompson, E. Appella, R.N. Perham, Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage: the V3 loop of HIV-1 gp120. J. Mol. Biol. 243, 167–172 (1994)

29.

L.L. Qiu, P.Y. Hua, L.L. Ye, Y.C. Wang, T. Qiu, H.Z. Bao, L. Wang, The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect. Prev. 31, 45–49 (2007)PubMedCrossRef

30.

T. Qiu, Q. Yang, X.R. Li, H. Yang, L.L. Qiu, L. Wang, Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters. Cancer Invest. 25, 563–568 (2007)PubMedCrossRef

31.

X. Zheng, Y. Han, Y. Li, Y. Yu, X. Yun, X. Ren, M. Gao, Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAF^V600E Mutational Status of 977 Cases. Ann. Surg. Oncol. 20, 2266–2273 (2013)PubMedCrossRef

32.

M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, K.A. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E.H. Holt, P. Hui, C.B. Umbricht, S. Basaria, M. Ewertz, A.P. Tufaro, J.A. Califano, M.D. Ringel, M.A. Zeiger, D. Sidransky, P.W. Ladenson, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373–6379 (2005)PubMedCrossRef

33.

E. Puxeddu, S. Filetti, BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? Endocrine (2013). doi:10.1007/s12020-013-0139-0 PubMed

Title: Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters
Authors: Pengtao Pan
Xiaoyi Han
Fangqian Li
Qingfeng Fu
Xiang Gao
Hui Sun
Li Wang
Publication date: 01-11-2014
Publisher: Springer US
Published in: Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0243-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves’ disease: a single-center experience

Sustained high levels of serum leptin rather than IL-6 observed in patients with postpartum thyroiditis during their first postpartum year

Pro: endoscopic endonasal transsphenoidal pituitary surgery is superior to microscope-based transsphenoidal surgery

Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing’s disease

The associations between cardiometabolic risk factors and visceral fat measured by a new dual-energy X-ray absorptiometry-derived method in lean healthy Caucasian women

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page